EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis

Agnieszka Wichtowska iD, Małgorzata Olejnik iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262210990 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Agnieszka Wichtowska und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Preclinical Sciences, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, 87-100 Torun, Poland. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dog Diseases, Cytokines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Canine atopic dermatitis (cAD) is a chronic, pruritic, inflammatory skin disease with complex immunopathogenesis involving dysregulated cytokine networks. In recent years, targeted therapies have transformed the management of cAD by directly or indirectly modulating cytokine activity. Lokivetmab, a monoclonal antibody neutralizing interleukin-31, represents a breakthrough in veterinary dermatology, providing rapid and sustained reduction in pruritus with a favorable safety profile. Janus kinase inhibitors, including oclacitinib and the newer ilunocitinib, act downstream by blocking cytokine signal transduction, offering effective control of both acute and chronic phases of disease. Ciclosporin, a calcineurin inhibitor, remains a valuable immunosuppressant for long-term cAD management, while topical tacrolimus provides localized benefits. Together, these therapies mark a paradigm shift from non-specific immunosuppressants to precision medicine. In this context, precision medicine refers to therapeutic strategies that selectively target key cytokines or intracellular signaling pathways central to the pathogenesis of cAD, such as IL-31 or the JAK/STAT axis. Unlike traditional immunosuppressants such as glucocorticoids, which exert broad and non-selective immune suppression, these agents modulate defined molecular mechanisms, thereby improving efficacy and minimizing adverse effects. Consequently, they enable improved quality of life for affected dogs and their owners. Future strategies will likely focus on patient stratification and personalized approaches based on immunological endotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicDog DiseasesCytokinesAnimalsDogsImmunosuppressive AgentsSignal Transduction

Stichwörter der Autor:innen

canine atopic dermatitisciclosporincytokinesilunocitinibimmunotherapylokivetmaboclacitinib

Substanzen

CytokinesImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Basic and Preclinical Sciences, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, 87-100 Torun, Poland.

ORCID-Profile: Agnieszka Wichtowska, Małgorzata Olejnik

Zitieren

APA

Wichtowska, A., & Olejnik, M. (2025). Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210990

Vancouver

Wichtowska A, Olejnik M. Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210990

BibTeX
@article{Wichtowska2025,
  author = {Wichtowska, Agnieszka and Olejnik, Małgorzata},
  title = {Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262210990}
}
Kostenlos starten →